Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis-Reference-Cited by-同舟云学术

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis

Published:2024-08-07 Issue:1 Volume:22 Page:
ISSN:1478-811X
Container-title:Cell Communication and Signaling
language:en
Short-container-title:Cell Commun Signal

Author:

Jiang Ling,Zhao Yu,Liu Fang,Huang Yun,Zhang Yujiao,Yuan Baoyi,Cheng Jiaying,Yan Ping,Ni Jinle,Jiang Yongshuai,Wu Quan,Jiang Xuejie

Funder

National Natural Science Foundation of China

Basic and Applied Basic Research Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12964-024-01774-9.pdf

Reference54 articles.

1. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG, Hoadley K, Triche TJ, Laird PW, Baty JD, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.

2. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, Böhmer FD, Gerke V, Schmidt-Arras D-E, Berdel WE, Müller-Tidow C, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36(2):326–39.

3. Gebru MT, Wang H-G. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):155.

4. Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164(1):61–72.

5. Piloto O, Wright M, Brown P, Kim K-T, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109(4):1643–52.